Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice

PLoS ONE

Volumn 4, Issue 12, 2009, Pages 1-9

  Chevaliez, Stéphane ^a,b   Bouvier Alias, Magali ^a,b   Brillet, Rozenn ^b   Pawlotsky, Jean Michel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; SPACER DNA; VIRUS PROTEIN;

5' UNTRANSLATED REGION; ACCURACY; AMINO ACID SEQUENCE; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG RESEARCH; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MOLECULAR PROBE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE HYBRIDIZATION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; STRAIN IDENTIFICATION; VIRUS STRAIN; ANALYTICAL EQUIPMENT; CLASSIFICATION; CLINICAL MEDICINE; DNA SEQUENCE; DRUG DESIGN; DRUG EFFECT; GENETICS; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; VIRUS GENE;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

ANTIVIRAL AGENTS; BASE SEQUENCE; CLINICAL MEDICINE; DNA, INTERGENIC; DRUG DESIGN; GENES, VIRAL; GENOTYPE; HEPACIVIRUS; MICROBIOLOGICAL TECHNIQUES; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 77949514845     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008209     Document Type: Article

References (39)

1. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-73.
2. Meffre C, Delarocque-Astagneau E, Pioche C, Dubois F, Roudot-Thoraval F, et al. (2007) Hepatitis C testing, care and treatment: evolution over ten years in France. Hepatology 46: 625A.
3. Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, et al. (2006) Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 131: 478-484.
4. Wasley A, Alter MJ (2000) Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20: 1-16.
5. (2002) National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36 (suppl. 1): S3-S20.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
9. Pawlotsky JM, Chevaliez S, McHutchison JG (2007) The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132: 1979-1998.
10. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, et al. (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360: 1839-1850.
11. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, et al. (2009) HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C. J Hepatol 50 (suppl. 1): S4.
12. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, et al. (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360: 1827-1838.
13. Erhardt A, Deterding K, Benhamou Y, Reiser M, Forns X, et al. (2009) Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther 14: 23-32.
14. Jiang LJ, Gai Y, Middleton T, Kurtz K, Lu L, et al. (2009) Potent HCV protease inhibitors with the potential for once-daily dosing and broad genotype coverage. J Hepatol 50 (suppl. 1): S6.
15. Liang Y, Ishida H, Lenz O, Lin TI, Nyanguile O, et al. (2008) Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 135: 1710-1718.
16. Nettles R, Chien C, Chung E, Persson A, Gao M, et al. (2008) BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology 48 (suppl. 1): 1025A.
17. Thompson P, Patel R, Steffy K, Appleman J (2009) Preclinical studies of ANA598 combined with other anti-HCV agents demonstrate potential of combination treatment. J Hepatol 50 (suppl. 1): S37.
18. Pawlotsky JM (2009) Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Ther Adv Gastroenterol 2: 205-219.
19. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I (2009) GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 53: 2129-2132.
20. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, et al. (2007) Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46: 631-639.
21. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, et al. (2007) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132: 1767-1777.
22. Villano S, Howe A, Raible D, Harper D, Speth J, et al. (2006) Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients. Hepatology 44 (suppl. 1): 607A-608A.
23. Chevaliez S, Pawlotsky JM (2008) Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol 22: 1031-1048.
24. Nolte FS (2001) Hepatitis C virus genotyping: clinical implications and methods. Mol Diagn 6: 265-277.
25. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, et al. (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74: 2391-2399.
26. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, et al. (2006) Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 131: 1040-1048.
27. Qiu P, Cai XY, Ding W, Zhang Q, Norris ED, et al. (2009) HCV genotyping using statistical classification approach. J Biomed Sci 16: 62.
28. Chen Z, Weck KE (2002) Hepatitis C virus genotyping: interrogation of the 59 untranslated region cannot accurately distinguish genotypes 1a and 1b. J Clin Microbiol 40: 3127-3134.
29. Ross RS, Viazov S, Roggendorf M (2007) Genotyping of hepatitis C virus isolates by a new line probe assay using sequence information from both the 59untranslated and the core regions. J Virol Methods 143: 153-160.
30. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, et al. (2007) Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 45: 1140-1145.
31. Nolte FS, Green AM, Fiebelkorn KR, Caliendo AM, Sturchio C, et al. (2003) Clinical evaluation of two methods for genotyping hepatitis C virus based on analysis of the 59 noncoding region. J Clin Microbiol 41: 1558-1564.
32. Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, et al. (2008) Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 46: 1901-1906.
33. Martro E, Gonzalez V, Buckton AJ, Saludes V, Fernandez G, et al. (2008) Evaluation of a new assay in comparison with reverse hybridization and sequencing methods for hepatitis C virus genotyping targeting both 59 noncoding and nonstructural 5B genomic regions. J Clin Microbiol 46: 192-197.
34. Morice Y, Roulot D, Grando V, Stirnemann J, Gault E, et al. (2001) Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. J Gen Virol 82: 1001-1012.
35. Felsenstein J (1993) PHYLIP: phylogeny inference package, version 3.5c (computer program). Distributed by the author. Department of Genetics, University of Washington, Seattle.
36. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
37. Salemi M, Vandamme AM (2002) Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J Mol Evol 54: 62-70.
38. Huson DH, Richter DC, Rausch C, Dezulian T, Franz M, et al. (2007) Dendroscope: an interactive viewer for large phylogenetic trees. BMC Bioinformatics 8: 460.
39. Perriere G, Gouy M (1996) WWW-query: an on-line retrieval system for biological sequence banks. Biochimie 78: 364-369.